Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriacae: Pharmacokinetic/pharmacodynamic considerations

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 1, 2008, Pages 166-168

  Macgowan, A ^a  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

Escherichia coli; Extended spectrum b lactamase; Monte Carlo simulation; Pharmacodynamics; Pharmacokinetics; Review

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DIHYDROFOLATE REDUCTASE INHIBITOR; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMOCILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ESCHERICHIA COLI;

EID: 37249076871     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01859.x     Document Type: Review

References (8)

1. Jacoby GA, Munoz-Price LS. The new β-lactamases. N Engl J Med 2005; 352: 380-391.
2. Paterson DL, Mulazimoglu L, Casellas JM et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteraemia. Clin Infect Dis 2000; 430: 473-478.
3. Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale CH, Murakawa T, Ambrose PG, eds, Antimicrobial pharmacodynamics in theory and clinical practice. Basel: Marcel Dekker, 2002; 1-22.
4. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: Pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11 (suppl 6): 10-17.
5. Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother 2005; 49: 276-280.
6. Ambrose PG, Grasela DM. The use of Monte-Carlo simulations to examine pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38: 151-157.
7. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended spectrum β-lactamases: Report from ARREST Program. Antimicrob Agents Chemother 2003; 47: 1643-1646.
8. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic modelling of carbapenems and fluoroquinolones against bacteria that produce extended spectrum beta lactamases. Clin Ther 2004; 28: 1800-1806.